JO2954B1 - Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptors - Google Patents
Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptorsInfo
- Publication number
- JO2954B1 JO2954B1 JO2007411A JOP20070411A JO2954B1 JO 2954 B1 JO2954 B1 JO 2954B1 JO 2007411 A JO2007411 A JO 2007411A JO P20070411 A JOP20070411 A JO P20070411A JO 2954 B1 JO2954 B1 JO 2954B1
- Authority
- JO
- Jordan
- Prior art keywords
- disorders
- psychosis
- treatment
- schizophrenia
- ht2a
- Prior art date
Links
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 title abstract 3
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 title abstract 3
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 201000000980 schizophrenia Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 abstract 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000002545 drug psychosis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002964 excitative effect Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84907006P | 2006-10-03 | 2006-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO2954B1 true JO2954B1 (en) | 2016-03-15 |
Family
ID=38926423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JO2007411A JO2954B1 (en) | 2006-10-03 | 2007-10-03 | Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptors |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US9434692B2 (https=) |
| EP (1) | EP2066641B1 (https=) |
| JP (2) | JP5346292B2 (https=) |
| CN (2) | CN102838546B (https=) |
| AR (1) | AR063100A1 (https=) |
| AU (1) | AU2007305235C1 (https=) |
| CA (1) | CA2664398C (https=) |
| CL (1) | CL2007002859A1 (https=) |
| ES (1) | ES2494846T3 (https=) |
| JO (1) | JO2954B1 (https=) |
| PA (1) | PA8749401A1 (https=) |
| PE (1) | PE20081454A1 (https=) |
| TW (1) | TWI415845B (https=) |
| WO (1) | WO2008042388A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| CA2646076C (en) | 2006-05-18 | 2015-06-30 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| JP5286254B2 (ja) | 2006-05-18 | 2013-09-11 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ａセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法 |
| ES2536762T3 (es) | 2006-05-18 | 2015-05-28 | Arena Pharmaceuticals, Inc. | Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| WO2008054748A2 (en) * | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| CN104739829B (zh) | 2008-10-28 | 2018-11-06 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| PL3575792T3 (pl) * | 2011-05-31 | 2023-03-27 | Biogen Ma Inc. | Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml) |
| WO2013010169A1 (en) | 2011-07-14 | 2013-01-17 | Cook Medical Technologies Llc | A sling to be used in the treatment of obstructive sleep apnea |
| CA2888030A1 (en) | 2012-10-16 | 2014-11-27 | Cook Medical Technologies Llc | Method and apparatus for treating obstructive sleep apnea (osa) |
| EP3498239B1 (en) | 2013-08-01 | 2021-04-21 | Cook Medical Technologies LLC | Tissue adjustment implant |
| AU2014306232B2 (en) | 2013-08-05 | 2018-12-06 | C2Dx, Inc. | Medical devices having a releasable tubular member and methods of using the same |
| CN104906682A (zh) | 2014-01-24 | 2015-09-16 | 史蒂文·沙勒布瓦 | 铰接气囊导管及其使用方法 |
| US9974563B2 (en) | 2014-05-28 | 2018-05-22 | Cook Medical Technologies Llc | Medical devices having a releasable member and methods of using the same |
| EP3177219B1 (en) | 2014-08-04 | 2018-09-26 | Cook Medical Technologies LLC | Medical devices having a releasable tubular member |
| WO2016051226A1 (en) * | 2014-09-29 | 2016-04-07 | Hitachi, Ltd. | Management system for computer system |
| WO2016201373A1 (en) * | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| EP3263567A1 (en) * | 2016-07-01 | 2018-01-03 | AiCuris Anti-infective Cures GmbH | Carboxamide-substituted pyrazoles and tri(hetero)aryl-pyrazoles for use in methods of treating and / or preventing cardiovascular diseases and / or comorbidities thereof |
| JP6650852B2 (ja) * | 2016-09-14 | 2020-02-19 | マルハニチロ株式会社 | ドコサヘキサエン酸を含有する睡眠の質改善剤 |
| SG11201906289YA (en) * | 2017-01-13 | 2019-08-27 | Sumitomo Dainippon Pharma Co Ltd | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
| CN111093572A (zh) | 2017-06-29 | 2020-05-01 | 库克医学技术有限责任公司 | 用于重新定位组织的可植入医疗装置 |
| EP3684463B1 (en) | 2017-09-19 | 2025-05-14 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| CN113382683A (zh) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | 改善睡眠的系统和方法 |
| PT3947360T (pt) | 2019-03-28 | 2024-09-20 | Zoetis Services Llc | Compostos inibidores da serotonina 5-ht2b |
| WO2022235531A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Movement disorders |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US654472A (en) * | 1900-02-03 | 1900-07-24 | George A Mayer | Hub-attaching device. |
| DE1643310A1 (de) | 1966-12-29 | 1971-06-03 | Dow Chemical Co | 4-Alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamin und seine pharmakologisch vertraeglichen Salze |
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| DE2926517A1 (de) | 1979-06-30 | 1981-01-15 | Beiersdorf Ag | Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| IL61721A (en) | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4555399A (en) | 1983-11-18 | 1985-11-26 | Key Pharmaceuticals, Inc. | Aspirin tablet |
| US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| EP0412798A3 (en) | 1989-08-08 | 1992-07-01 | Merck Sharp & Dohme Ltd. | Substituted pyridines, their preparation, formulations and use in dementia |
| US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
| US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| US5128351A (en) | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
| JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
| FR2682379B1 (fr) | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
| FR2690440B1 (fr) | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
| US5905080A (en) | 1993-08-20 | 1999-05-18 | Smithkline Beecham, P.L.C. | Amide and urea derivatives as 5HT1D receptor antagonists |
| FR2722369B1 (fr) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides |
| EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| CA2135253A1 (en) | 1994-11-07 | 1996-05-08 | Michael Dennis | Compound screening based on a window of chemical-messenger-independent activity |
| US6540981B2 (en) | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
| RO115522B1 (ro) | 1995-02-02 | 2000-03-30 | Smithkline Beecham P.L.C. | Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DK0822808T3 (da) | 1995-04-20 | 2000-10-09 | Eurand Int | Kompositmateriale med natriumstivelsesglycolat som bærermateriale og produkter deraf |
| US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| GB9607219D0 (en) | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| US6417393B1 (en) | 1996-05-24 | 2002-07-09 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
| AU2962297A (en) | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
| CZ425698A3 (cs) | 1996-06-27 | 1999-06-16 | Smithkline Beecham Corporation | Antagonista IL-8 receptoru |
| WO1998000016A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| WO1998000133A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate |
| ATE314054T1 (de) | 1996-10-25 | 2006-01-15 | Shire Lab Inc | Osmotisches verabreichungssystem für lösliche dosen |
| JP2001508767A (ja) | 1996-12-02 | 2001-07-03 | 藤沢薬品工業株式会社 | ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体 |
| US6420541B1 (en) | 1998-04-14 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
| TR199902593T2 (xx) | 1997-04-22 | 2000-03-21 | Neurosearch A/S | �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�. |
| US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| CA2294064A1 (en) | 1997-07-29 | 1999-02-11 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AU750125B2 (en) | 1997-08-27 | 2002-07-11 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| BR9813331A (pt) | 1997-10-31 | 2000-08-22 | Aventis Pharma Ltd | Composto, uso do mesmo, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano que sofra ou esteja sujeito a condições que possam ser melhoradas pela administração de um inibidor da adesão celular mediada pela a4b1, e, resina |
| JPH11183942A (ja) | 1997-12-19 | 1999-07-09 | Nippon Mitsubishi Oil Corp | エレクトロクロミック素子 |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| BR9814375A (pt) | 1997-12-22 | 2002-05-21 | Bayer Ag | Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas |
| JP3887769B2 (ja) | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害 |
| MXPA00010060A (es) | 1998-04-14 | 2004-04-23 | Arena Pharm Inc | Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos. |
| US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
| OA11665A (en) | 1998-10-22 | 2004-12-08 | Neurosearch As | Substituted phenyl derivatives, their preparation and use. |
| US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
| CA2368631A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
| US6469006B1 (en) * | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
| IT1312115B1 (it) | 1999-06-24 | 2002-04-04 | Nicox Sa | Composti amorfi e relative composizioni farmaceutiche |
| SK1182002A3 (en) | 1999-07-28 | 2002-11-06 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| US6541477B2 (en) | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| EP1108720A1 (en) | 1999-12-08 | 2001-06-20 | Basf Aktiengesellschaft | Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines |
| WO2001044193A1 (en) | 1999-12-16 | 2001-06-21 | Biostream Therapeutics | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
| MXPA02006137A (es) | 1999-12-20 | 2002-12-05 | Neuromed Tech Inc | Bloqueadores del canal de calcio parcialmente saturados. |
| AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
| FR2810979B1 (fr) | 2000-06-29 | 2002-08-23 | Adir | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
| WO2002039987A2 (en) | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| AR035521A1 (es) | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| WO2002076464A1 (en) | 2001-03-22 | 2002-10-03 | Arena Pharmaceuticals, Inc. | Anti-psychosis combination |
| ATE377413T1 (de) | 2001-06-29 | 2007-11-15 | Eurand Pharmaceuticals Ltd | Verfahren für die thermodynamische aktivierung von wasserlöslichen arzneimitteln, die in vernetzten polymeren geladen sind |
| JP4733877B2 (ja) | 2001-08-15 | 2011-07-27 | 富士通セミコンダクター株式会社 | 半導体装置 |
| CA2461202C (en) | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| WO2004028450A2 (en) | 2002-09-24 | 2004-04-08 | Arena Pharmaceuticals, Inc. | Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| TW200735568A (en) | 2002-11-08 | 2007-09-16 | Interdigital Tech Corp | Composite channel quality estimation techniques for wireless receivers |
| JPWO2004046110A1 (ja) | 2002-11-15 | 2006-03-16 | アステラス製薬株式会社 | メラニン凝集ホルモン受容体拮抗剤 |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20060229335A1 (en) | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
| WO2004085433A2 (en) | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| FR2855825B1 (fr) * | 2003-06-04 | 2008-08-22 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
| PT1558582E (pt) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo |
| SI1558582T1 (sl) | 2003-07-22 | 2006-06-30 | Arena Pharm Inc | Diaril in arilheteroaril secninski derivati kot modulatorji 5-HT2A serotoninskega receptorja, koristnega za profilakso in zdravljenje motenj, ki so znjim povezane |
| CA2533112A1 (en) | 2003-08-13 | 2005-03-03 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
| US7091236B1 (en) | 2003-08-20 | 2006-08-15 | Sciele Pharma, Inc. | Method for increasing the bioavailability of glycopyrrolate |
| US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
| EP1664042A1 (en) | 2003-09-03 | 2006-06-07 | Galapagos N.V. | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS |
| DE10354604B4 (de) * | 2003-11-21 | 2016-10-13 | Gesellschaft für Aufladetechnik und Spindelbau mbH | Stufenlos schaltbares, magnetodynamisches Getriebe |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| CA2559038C (en) | 2004-03-23 | 2013-09-10 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof |
| US20060014705A1 (en) | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
| US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
| JP2008509982A (ja) | 2004-08-16 | 2008-04-03 | プロシディオン・リミテッド | アリール尿素誘導体 |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| AU2005302669A1 (en) | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as CB1 antagonists |
| US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| JP2008518935A (ja) | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006060654A2 (en) | 2004-12-01 | 2006-06-08 | Divergence, Inc. | Pesticidal compositions and methods |
| WO2006060762A2 (en) | 2004-12-03 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| EP1831172B1 (en) | 2004-12-28 | 2009-02-18 | Council of Scientific and Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| WO2006076592A1 (en) | 2005-01-14 | 2006-07-20 | Cgi Pharmaceuticals, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| EP1843762A1 (en) | 2005-01-19 | 2007-10-17 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| CN101166516A (zh) | 2005-01-21 | 2008-04-23 | 特瓦制药工业有限公司 | 稳定的唑尼沙胺药物制剂及其制备方法 |
| AR052886A1 (es) | 2005-01-26 | 2007-04-11 | Arena Pharm Inc | Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis |
| EP1846415B1 (en) | 2005-01-27 | 2012-08-01 | Janssen Pharmaceutica NV | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
| GT200600042A (es) | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP5049267B2 (ja) | 2005-04-26 | 2012-10-17 | ハイプニオン・インコーポレイテッド | ベンズイソオキサゾールピペラジン化合物およびその使用方法 |
| EP1734039A1 (en) | 2005-06-13 | 2006-12-20 | Esbatech AG | Aryl urea compounds as BETA-secretase inhibitors |
| US8703805B2 (en) | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| US7754724B2 (en) * | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7544685B2 (en) | 2005-08-17 | 2009-06-09 | H. Lundbeck A/S | 2,3-dihydroindole compounds |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| CN101272771A (zh) | 2005-09-29 | 2008-09-24 | 艾尼纳制药公司 | 可用于治疗相关病症的5－ht2a血清素受体调节剂的医药组合物 |
| WO2007120600A2 (en) | 2006-04-10 | 2007-10-25 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| GB0608655D0 (en) | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
| ES2536762T3 (es) | 2006-05-18 | 2015-05-28 | Arena Pharmaceuticals, Inc. | Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este |
| EP2051978A2 (en) | 2006-05-18 | 2009-04-29 | Arena Pharmaceuticals, Inc. | Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| JP5286254B2 (ja) | 2006-05-18 | 2013-09-11 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ａセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法 |
| CA2646076C (en) | 2006-05-18 | 2015-06-30 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| JP2010502618A (ja) | 2006-08-31 | 2010-01-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | セロトニン５−ｈｔ２ａ受容体のモジュレータとしてのベンゾフラン誘導体 |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| TW200823204A (en) | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| WO2008054748A2 (en) | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| US9034890B2 (en) | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| US8969402B2 (en) | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| KR20090094125A (ko) * | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| CN104739829B (zh) | 2008-10-28 | 2018-11-06 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| EP2911670A1 (en) | 2012-10-25 | 2015-09-02 | Otsuka Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
| WO2014085362A1 (en) | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
| KR101472682B1 (ko) | 2013-07-23 | 2014-12-15 | 고려대학교 산학협력단 | 메타물질 제조 방법, 이에 의해 제조된 메타물질 구조 필름 및 이를 이용한 광학 이미징 시스템 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
-
2007
- 2007-09-28 TW TW096136466A patent/TWI415845B/zh not_active IP Right Cessation
- 2007-10-02 WO PCT/US2007/021182 patent/WO2008042388A1/en not_active Ceased
- 2007-10-02 EP EP07839161.2A patent/EP2066641B1/en active Active
- 2007-10-02 CA CA2664398A patent/CA2664398C/en active Active
- 2007-10-02 AU AU2007305235A patent/AU2007305235C1/en not_active Ceased
- 2007-10-02 CN CN201210300858.0A patent/CN102838546B/zh not_active Expired - Fee Related
- 2007-10-02 US US12/444,098 patent/US9434692B2/en active Active
- 2007-10-02 ES ES07839161.2T patent/ES2494846T3/es active Active
- 2007-10-02 CN CN2007800371033A patent/CN101611013B/zh not_active Expired - Fee Related
- 2007-10-02 AR ARP070104362A patent/AR063100A1/es active IP Right Grant
- 2007-10-02 JP JP2009531423A patent/JP5346292B2/ja not_active Expired - Fee Related
- 2007-10-03 CL CL200702859A patent/CL2007002859A1/es unknown
- 2007-10-03 JO JO2007411A patent/JO2954B1/en active
- 2007-10-03 PE PE2007001335A patent/PE20081454A1/es active IP Right Grant
- 2007-10-03 PA PA20078749401A patent/PA8749401A1/es unknown
-
2012
- 2012-09-13 US US13/614,537 patent/US20130217700A1/en not_active Abandoned
-
2013
- 2013-07-05 JP JP2013141517A patent/JP2013199493A/ja not_active Withdrawn
-
2015
- 2015-04-22 US US14/692,807 patent/US9732039B2/en active Active
-
2017
- 2017-07-24 US US15/657,896 patent/US10351531B2/en active Active
-
2019
- 2019-04-18 US US16/388,533 patent/US20200048205A1/en not_active Abandoned
-
2021
- 2021-02-18 US US17/178,916 patent/US20210380537A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PA8749401A1 (es) | 2009-02-09 |
| AU2007305235C1 (en) | 2012-12-13 |
| US10351531B2 (en) | 2019-07-16 |
| JP5346292B2 (ja) | 2013-11-20 |
| US9732039B2 (en) | 2017-08-15 |
| CL2007002859A1 (es) | 2008-06-06 |
| WO2008042388A1 (en) | 2008-04-10 |
| US20100004264A1 (en) | 2010-01-07 |
| US20130217700A1 (en) | 2013-08-22 |
| TW200823201A (en) | 2008-06-01 |
| US20210380537A1 (en) | 2021-12-09 |
| CN102838546B (zh) | 2015-07-15 |
| US20200048205A1 (en) | 2020-02-13 |
| EP2066641A1 (en) | 2009-06-10 |
| JP2010505832A (ja) | 2010-02-25 |
| CN101611013A (zh) | 2009-12-23 |
| AU2007305235A1 (en) | 2008-04-10 |
| JP2013199493A (ja) | 2013-10-03 |
| AR063100A1 (es) | 2008-12-30 |
| US9434692B2 (en) | 2016-09-06 |
| PE20081454A1 (es) | 2008-10-18 |
| EP2066641B1 (en) | 2014-06-04 |
| CN101611013B (zh) | 2012-09-05 |
| ES2494846T3 (es) | 2014-09-16 |
| CA2664398C (en) | 2018-03-13 |
| CA2664398A1 (en) | 2008-04-10 |
| CN102838546A (zh) | 2012-12-26 |
| US20160075660A1 (en) | 2016-03-17 |
| TWI415845B (zh) | 2013-11-21 |
| AU2007305235B2 (en) | 2012-05-17 |
| US20170320831A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2954B1 (en) | Pirazol derivatives used as serotonin 5-Ht2a receptor controllers useful in the treatment of disorders related to these receptors | |
| WO2008054748A3 (en) | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| TW200618798A (en) | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | |
| WO2009023253A3 (en) | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | |
| WO2007120600A3 (en) | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| WO2006060762A3 (en) | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| WO2007136680A3 (en) | 3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| MY141862A (en) | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | |
| WO2007136875A3 (en) | Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| WO2003062206A3 (en) | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto | |
| WO2010062323A3 (en) | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto | |
| EA200800971A1 (ru) | Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений | |
| JP5545955B2 (ja) | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 | |
| MX2010013020A (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| PE20080944A1 (es) | Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| WO2007112675A8 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
| TN2009000095A1 (en) | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | |
| MX2009004807A (es) | Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa. | |
| KR20100134667A (ko) | Ｎｋ3 길항제로서의 이소퀴놀리논 유도체 | |
| JP2014512411A (ja) | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 | |
| BRPI0907627A2 (pt) | Derivados de piperidina sulfonamidas | |
| GEP20104961B (en) | 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto | |
| Giardina et al. | A novel, nonpeptidic, orally active bivalent inhibitor of human β-tryptase | |
| TH86939B (th) | อนุพันธ์ไดแอริลและแอริลเฮเทโรแอริลยูเรียเป็นมอดูเลเตอร์ของ 5-ht2a เซอโรโทนินรีเซปเตอร์ที่มีประโยชน์สำหรับการป้องกันและการบำบัดความผิดปกติที่เกี่ยวกับมัน |